GlassScriptPhysician profile
Joseph P Behan
NPI 1619992625
$7,229.13
in general payments reported to CMS, 2019-2025
22 companies · $3,626 in 2025
The $3,626 reported for 2025 was more than what 96% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $152 · 2020: $198 · 2021: $209 · 2022: $488 · 2023: $323 · 2024: $2,234 · 2025: $3,626.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $5,600 · Food and Beverage: $583.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $5,600.00 |
| Food and Beverage | $582.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mimedx Group, INC. | $5,600.00 | 2024-2025 | Bovine Collagen |
| Myovant Sciences INC. | $363.45 | 2021-2022 | |
| Abbvie INC. | $358.23 | 2019-2023 | Lo Loestrin Fe |
| Myriad Women'S Health, INC. | $98.99 | 2023 | Myrisk |
| Astellas Pharma US INC | $96.19 | 2024 | Veozah |
| Hologic Sales and Service, LLC | $95.94 | 2022-2023 | Coolseal Generator, Acessa Provu System |
| Pfizer INC. | $88.66 | 2022-2025 | |
| Aspira Women'S Health INC | $87.58 | 2022 | |
| Shield Therapeutics INC | $78.42 | 2023-2024 | Accrufer |
| Millicent US INC | $70.58 | 2020 | |
| Amag Pharmaceuticals, INC. | $52.62 | 2019-2020 | |
| Therapeuticsmd, INC. | $40.55 | 2019-2020 | |
| Cumberland Pharmaceuticals, INC. | $36.03 | 2023-2024 | Caldolor |
| Davol INC. | $34.49 | 2024 | Arista Ah Flexitip |
| Sage Therapeutics, LLC | $28.68 | 2022-2023 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Minerva Surgical, INC | $23.03 | 2023 | |
| Coopersurgical, INC. | $18.21 | 2024 | |
| Daiichi Sankyo INC. | $15.14 | 2023 | Enhertu |
| Roche Diagnostics Corporation | $14.08 | 2021 | |
| Medicem INC. | $11.49 | 2021 | |
| Exeltis, USA INC. | $11.04 | 2019 | |
| Mission Pharmacal Company | $5.73 | 2024 | Citranatal Medley |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Behan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.